Nonpegylated G-CSF was used more commonly than pegylated formulations, and G-CSF was mainly used as secondary prophylaxis, which is consistent with consensus recommendations that primary prophylactic G-CSF use is reserved for chemotherapy regimens with a high (≥20%) risk of febrile neutropenia, and secondary prophylaxis is used in patients who experience febrile neutropenia or dose-limiting neutropenia in a previous treatment cycle (20, 21). Here, CSF3 is linked to neutropenia.